Early diagnostic value of two-dimensional speck-tracking echocardiography combined with long non-coding RNA and metastasis associated in lung adenocarcinoma transcript 1 in septic cardiomyopathy

doi:10.3877/cma.j.issn.1674-6880.2022.03.002

Abstract

Abstract:

Objective

To investigate the diagnostic value of two-dimensional speck-tracking echocardiography (2D-STE) combined with long non-coding RNA (lncRNA) and metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) in septic cardiomyopathy (SCM).

Methods

A total of 86 septic patients admitted to the Department of Emergency Intensive Care Unit of Ningbo Huamei Hospital, University of Chinese Academy of Sciences from January 2019 to January 2021 were selected. According to left ventricular ejection fraction (LVEF), 86 septic patients were divided into a SCM group (LVEF < 50%, n = 37) and a non-SCM group (LVEF ≥ 50%, n = 49). Clinical data, global longitudinal strain (GLS), global radial strain (GRS), global circumferential strain (GCS) and serum lncRNA-MALAT1 of the two groups were analyzed. The binary Logistic regression was used to analyze the risk factors affecting the prognosis of patients with SCM, and the receiver operating characteristic (ROC) curve was used to analyze the early diagnostic values of GLS and serum lncRNA-MALAT1 in SCM.

Results

The N-terminal pro-B-type natriuretic peptide (NT-proBNP) [(2 389 ± 2 240) ng/L vs. (1 156 ± 716) ng/L, t = 3.620, P = 0.001], cardiac troponin I (cTnI) [(0.60 ± 0.41) μg/L vs. (0.35 ± 0.29) μg/L, t = 3.301, P = 0.001], GLS [(-18.6 ± 1.6)% vs. (-20.5 ± 2.0)%, t = 4.735, P = 0.001] and lncRNA-MALAT1 [(2.4 ± 0.5) vs. (2.0 ± 0.4), t = 4.219, P = 0.001] all showed significant differences between the SCM group and the non-SCM group. The binary Logistic regression analysis revealed that NT-proBNP [odds ratio (OR) = 0.999, 95% confidence interval (CI) (0.999, 1.000), P = 0.033], cTnI [OR = 0.143, 95%CI (0.024, 0.839), P = 0.031], GLS [OR = 0.543, 95%CI (0.361, 0.817), P = 0.003] and lncRNA-MALAT1 [OR = 0.059, 95%CI (0.011, 0.309), P = 0.001] were independent risk factors for SCM. The ROC curve analysis showed that NT-proBNP [area under the cure (AUC) = 0.697, 95%CI (0.588, 0.791), P = 0.001], cTnI [AUC = 0.681, 95%CI (0.572, 0.778), P = 0.003], GLS[AUC = 0.766, 95%CI (0.667, 0.866), P < 0.001], lncRNA-MALAT1 [AUC = 0.735, 95%CI (0.630, 0.840), P < 0.001] and GLS combined with lncRNA-MALAT1 [AUC = 0.845, 95%CI (0.764, 0.926), P < 0.001] had diagnostic values for SCM. In particular, GLS combined with lncRNA-MALAT1 had the best diagnostic value among these five markers.

Conclusion

The combination detection of 2D-STE and lncRNA-MALAT1 has diagnostic significance on sepsis-induced myocardial injury.

Key words: Septic cardiomyopathy, Long non-coding RNA, Metastasis associated in lung adenocarcinoma transcript 1, Two-dimensional speckle-tracking echocardiography

Yuanjie Le, Weidong Wang, Zhifei Ben. Early diagnostic value of two-dimensional speck-tracking echocardiography combined with long non-coding RNA and metastasis associated in lung adenocarcinoma transcript 1 in septic cardiomyopathy[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2022, 15(03): 183-188.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwzzyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6880.2022.03.002

https://zhwzzyxzz.cma-cmc.com.cn/EN/Y2022/V15/I03/183

Figures/Tables 4

References 20

1	Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. JAMA, 2016, 315 (8): 801-810.
2	Angus DC, van der Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013, 369 (9): 840-851.
3	Fernando SM, Rochwerg B, Seely AJE. Clinical implications of the third international consensus definitions for sepsis and septic shock (sepsis-3)[J]. CMAJ, 2018, 190 (36): E1058-E1059.
4	Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction[J]. Crit Care Med, 2007, 35 (10): 2408-2416.
5	Blanco J, Muriel-Bombín A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study[J]. Crit Care, 2008, 12 (6): R158.
6	Lanspa MJ, Pittman JE, Hirshberg EL, et al. Association of left ventricular longitudinal strain with central venous oxygen saturation and serum lactate in patients with early severe sepsis and septic shock[J]. Crit Care, 2015, 19 (1): 304.
7	Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring[J]. Circ Cardiovasc Imaging, 2009, 2 (5): 356-364.
8	黄爱蓉，梁冬施，金益梅，等. 非编码RNA在脓毒症心肌细胞中表达分析[J/CD]. 中华危重症医学杂志（电子版），2021，14（2）：113-119.
9	Zhuang YT, Xu DY, Wang GY, et al. IL-6 induced lncRNA MALAT1 enhances TNF-α expression in LPS-induced septic cardiomyocytes via activation of SAA3[J]. Eur Rev Med Pharmacol Sci, 2017, 21 (2): 302-309.
10	Yu Z, Rayile A, Zhang X, et al. Ulinastatin protects against lipopolysaccharide-induced cardiac microvascular endothelial cell dysfunction via downregulation of lncRNA MALAT1 and EZH2 in sepsis[J]. Int J Mol Med, 2017, 39 (5): 1269-1276.
11	Beesley SJ, Weber G, Sarge T, et al. Septic cardiomyopathy[J]. Crit Care Med, 2018, 46 (4): 625-634.
12	Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock[J]. Ann Intern Med, 1984, 100 (4): 483-490.
13	Papanikolaou J, Makris D, Mpaka M, et al. New insights into the mechanisms involved in B-type natriuretic peptide elevation and its prognostic value in septic patients[J]. Crit Care, 2014, 18 (3): R94.
14	Landesberg G, Jaffe AS, Gilon D, et al. Troponin elevation in severe sepsis and septic shock: the role of left ventricular diastolic dysfunction and right ventricular dilatation[J]. Crit Care Med. 2014, 42 (4): 790-800.
15	Leitman M, Lysyansky P, Sidenko S, et al. Two-dimensional strain-a novel software for real-time quantitative echocardiographic assessment of myocardial function[J]. J Am Soc Echocardiogr, 2004, 17 (10): 1021-1029.
16	Yingchoncharoen T, Agarwal S, Popovic ZB, et al. Normal ranges of left ventricular strain: a meta-analysis[J]. J Am Soc Echocardiogr, 2013, 26 (2): 185-191.
17	Qiu MT, Hu JW, Yin R, et al. Long noncoding RNA: an emerging paradigm of cacer research[J]. Tumour Biol, 2013, 34 (2): 613-620.
18	Wu Y, Huang C, Meng X, et al. Long noncoding RNA MALAT1: insights into its biogenesis and implications in human disease[J]. Curr Pharm Des, 2015, 21 (34): 5017-5028.
19	Wang S, Yao T, Deng F, et al. LncRNA MALAT1 promotes oxygen-glucose deprivation and reoxygenation induced cardiomyocytes injury through sponging miR-20b to enhance beclin1-mediated autphagy[J]. Cardiovasc Drugs Ther, 2019, 33 (6): 675-686.
20	Wang C, Liu G, Yang H, et al. MALAT1-mediated recruitment of the histone methyltransferase EZH2 to the microRNA-22 promoter leads to cardiomyocyte apoptosis in diabeic cardiomyopathy[J]. Sci Total Environ, 2021 (766): 142191.

组别	例数	年龄（岁）	性别（例，男/女）	去甲肾上腺素剂量（μg·kg^-1·min^-1）	乳酸（mmol/L）	C反应蛋白（mg/L）	降钙素原（μg/L）	NT-proBNP（ng/L）	cTnI（μg/L）
SCM组	37	58 ± 14	23/14	0.66 ± 0.43	5.6 ± 3.2	223 ± 72	23 ± 19	2 389 ± 2 240	0.60 ± 0.41
脓毒症无心肌损伤组	49	60 ± 12	31/18	0.81 ± 0.43	4.7 ± 2.2	187 ± 86	18 ± 10	1 156 ± 716	0.35 ± 0.29
t/χ²值		0.480	0.011	1.702	1.647	0.834	1.427	3.620	3.301
P值		0.633	0.917	0.092	0.103	0.201	0.157	0.001	0.001
组别	例数	lncRNA-MALAT1	SOFA评分（分）	APACHEⅡ评分（分）	感染部位[例（%）]
组别	例数	lncRNA-MALAT1	SOFA评分（分）	APACHEⅡ评分（分）	肺及胸腔	腹腔	泌尿系统	皮肤软组织	其他
SCM组	37	2.4 ± 0.5	9.2 ± 3.0	20.4 ± 5.5	9（24.3）	15（40.5）	6（16.2）	2（5.4）	5（13.5）
脓毒症无心肌损伤组	49	2.0 ± 0.4	8.0 ± 3.4	19.8 ± 4.9	16（32.7）	17（34.7）	8（16.3）	3（6.1）	5（10.2）
t/χ²值		4.219	1.801	0.545	1.137
P值		0.001	0.075	0.587	0.813

组别	例数	年龄（岁）	性别（例，男/女）	去甲肾上腺素剂量（μg·kg^-1·min^-1）	乳酸（mmol/L）	C反应蛋白（mg/L）	降钙素原（μg/L）	NT-proBNP（ng/L）	cTnI（μg/L）
SCM组	37	58 ± 14	23/14	0.66 ± 0.43	5.6 ± 3.2	223 ± 72	23 ± 19	2 389 ± 2 240	0.60 ± 0.41
脓毒症无心肌损伤组	49	60 ± 12	31/18	0.81 ± 0.43	4.7 ± 2.2	187 ± 86	18 ± 10	1 156 ± 716	0.35 ± 0.29
t/χ²值		0.480	0.011	1.702	1.647	0.834	1.427	3.620	3.301
P值		0.633	0.917	0.092	0.103	0.201	0.157	0.001	0.001
组别	例数	lncRNA-MALAT1	SOFA评分（分）	APACHEⅡ评分（分）	感染部位[例（%）]
组别	例数	lncRNA-MALAT1	SOFA评分（分）	APACHEⅡ评分（分）	肺及胸腔	腹腔	泌尿系统	皮肤软组织	其他
SCM组	37	2.4 ± 0.5	9.2 ± 3.0	20.4 ± 5.5	9（24.3）	15（40.5）	6（16.2）	2（5.4）	5（13.5）
脓毒症无心肌损伤组	49	2.0 ± 0.4	8.0 ± 3.4	19.8 ± 4.9	16（32.7）	17（34.7）	8（16.3）	3（6.1）	5（10.2）
t/χ²值		4.219	1.801	0.545	1.137
P值		0.001	0.075	0.587	0.813

组别	例数	GLS	GCS	GRS
SCM组	37	-18.6 ± 1.6	-19.2 ± 2.3	34.9 ± 3.7
脓毒症无心肌损伤组	49	-20.5 ± 2.0	-20.4 ± 2.1	35.8 ± 3.1
t值		4.735	1.206	0.627
P值		0.001	0.173	0.315

组别	例数	GLS	GCS	GRS
SCM组	37	-18.6 ± 1.6	-19.2 ± 2.3	34.9 ± 3.7
脓毒症无心肌损伤组	49	-20.5 ± 2.0	-20.4 ± 2.1	35.8 ± 3.1
t值		4.735	1.206	0.627
P值		0.001	0.173	0.315

危险因素	回归系数	标准误	Wald值	P值	OR值	95%CI
NT-proBNP（ng/L）	-0.001	0.005	4.523	0.033	0.999	0.999 ~ 1.000
cTnI（μg/L）	-1.946	0.903	4.639	0.031	0.143	0.024 ~ 0.839
GLS（%）	-0.611	0.208	8.598	0.003	0.543	0.361 ~ 0.817
lncRNA-MALAT1	-2.833	0.846	11.205	0.001	0.059	0.011 ~ 0.309

Please choose a citation manager

Content to export